The PROMIS study
576 men
MP-MRI followed by TRUS-biopsy (standard practice) & TPM-
biopsy (reference standard)
Clinically significant cancer:
MP-MRI versus TRUS-biopsy:
Sensitivity: 93% vs 48%
Specificity: 41% vs 96%
Ahmed HU et al. PROMIS study group. Lancet 2017;389(10071):815-822
Kapoor J et al. Eur Urol. 2017 Feb 23. pii: S0302-2838(17)30103-3.